Peginterferon alfa-2a, also known as pegylated interferon alfa-2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. Interferon alfa-2a is produced biosynthetically using recombinant DNA technology and is the product of a cloned human leukocyte interferon gene inserted into and expressed in Escherichia Coli. Peginterferon alfa-2a is indicated, together with ribavirin, for the treatment of Chronic Hepatitis C in adult patients without cirrhosis and in adult patients with compensated cirrhosis, including Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) co-infection patients with stable HIV disease, with or without, antiretroviral therapy. Peginterferon alfa-2a is also indicated as a monotherapy for the treatment of both Hepatitis B Viral Early Antigen (HBeAg)-positive and HBeAg-negative chronic hepatitis B in patients with compensated liver disease, liver inflammation and evidence of viral replication.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Peginterferon Alfa-2a, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.